WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 13, 2026, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will provide an overview of the Company’s pro ...

Key Takeaways KYMR surged after KT-621 showed deep STAT6 degradation and strong EASI and pruritus reductions.KT-621 cut multiple type 2 biomarkers and was mostly safe, supporting its potential as a once-daily therapy.FDA Fast Track and ongoing phase IIb AD and asthma studies position KT-621 for broader late-stage development.Kymera Therapeutics, Inc. (KYMR) has put up a stupendous performance over the past year. Shares of this clinical-stage biotechnology company have surged 82.4% over the said time frame c ...

Core Insights - Kymera Therapeutics, Inc. (KYMR) received FDA Fast Track designation for KT-621, aimed at treating moderate to severe atopic dermatitis, which is the most common form of eczema [1][8] - KYMR's stock increased by 4.23% in after-hours trading following the announcement [1] - KT-621 is a first-in-class, once-daily oral degrader of STAT6, a key transcription factor in Type 2 inflammation [1] FDA Designation - The Fast Track designation from the FDA accelerates the development and review process for drugs addressing serious conditions and unmet medical needs, allowing for frequent interactions with the FDA during clinical development [2] Clinical Development - Positive results were reported from the phase Ib study, BroADen AD, where KT-621 showed effectiveness across various measures, including STAT6 degradation and safety [3] - A phase IIb study, BROADEN2, is ongoing with data expected by mid-2027, and a phase IIb study for asthma is planned to start in Q1 2026 [4] Financial Performance - Kymera closed an upsized underwritten public offering, raising $602 million by selling 8,050,000 shares at $86 per share, with gross proceeds of approximately $692.3 million [5] - The company's stock has surged 64.1% year to date in 2025, outperforming the industry gain of 17.7% [6][7] Pipeline and Collaborations - Kymera is utilizing targeted protein degradation (TPD) to develop drugs for significant health issues, with promising progress in its pipeline [9] - In June 2025, Kymera entered an exclusive agreement with Gilead Sciences to develop a novel molecular glue degrader program targeting CDK2 for oncology applications [10][11] - Kymera also collaborates with Sanofi to advance its pipeline, with a candidate targeting IRAK4 selected for clinical studies [12]

Core Viewpoint - Kymera Therapeutics, Inc. has successfully closed an upsized underwritten public offering, raising $602.0 million through the sale of 8,050,000 shares of common stock at a price of $86.00 per share, resulting in gross proceeds of approximately $692.3 million before expenses [1][2]. Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on developing targeted protein degradation (TPD) therapies for immunological diseases, aiming to create a new generation of oral small molecule degrader medicines [6]. - The company has advanced its first degrader into clinical trials and is committed to building a robust pipeline of innovative therapies that address critical health issues [6]. - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [6]. Offering Details - The public offering was managed by a consortium of financial institutions including Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities, and Wells Fargo Securities [2]. - The offering was conducted under an automatically effective shelf registration statement filed with the SEC on October 31, 2024 [3]. - A final prospectus supplement detailing the terms of the offering has been filed with the SEC and is available for public access [4].

Core Insights - The FDA has granted Fast Track designation to KT-621, a first-in-class oral STAT6 degrader for treating moderate to severe atopic dermatitis (AD) [1][2][3] - KT-621 aims to provide a once-daily oral treatment option that matches the efficacy and safety of injectable biologics, addressing significant gaps in current treatment options for AD and other Type 2-driven diseases [2][4] - Positive results from the BroADen Phase 1b trial indicate KT-621's potential in treating Type 2 inflammatory diseases, with ongoing Phase 2b trials expected to yield data by mid-2027 [1][2][4] Company Overview - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][6] - The company has advanced the first degrader into clinical evaluation for immunological diseases and aims to build a leading pipeline of therapies [6] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces [6] Atopic Dermatitis Context - Atopic dermatitis is a chronic inflammatory disease that significantly impacts patients' quality of life, with a notable unmet need for improved treatment options [5] - Current treatments include topical therapies and injectable biologics, but many patients remain untreated [5]

Core Viewpoint - Kymera Therapeutics, Inc. has announced a public offering of $602.0 million in common stock to advance its pipeline of degrader programs and for general corporate purposes [1][2]. Group 1: Offering Details - Kymera is selling 7,000,000 shares at a public offering price of $86.00 per share, with an additional option for underwriters to purchase up to 1,050,000 shares [1]. - The gross proceeds from the offering are expected to be approximately $602.0 million before deducting underwriting discounts and commissions [1]. - The offering is anticipated to close on December 11, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance Kymera's pipeline of preclinical and clinical degrader programs targeting large patient populations and for working capital [2]. Group 3: Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop innovative medicines for immunological diseases [6]. - The company aims to provide a new generation of oral small molecule therapies that are highly effective and convenient for patients [6].

Core Viewpoint - Kymera Therapeutics, Inc. (NASDAQ:KYMR) has experienced significant stock performance, reaching an all-time high following positive clinical trial results for its eczema treatment, KT-621 [1][3]. Stock Performance - During intra-day trading, Kymera's stock price peaked at $103 before closing at $94.30, reflecting a 41.55 percent increase [2]. Clinical Trial Results - The clinical trial for KT-621 involved 22 patients over four weeks, resulting in a nearly complete elimination of the transcription factor STAT6, which is associated with allergic inflammation, by 98 percent in blood and 94 percent in skin [3]. Fundraising Plans - Kymera Therapeutics announced plans to raise $500 million through the issuance of new shares, with the potential to increase this amount to $575 million [4]. - The proceeds from this offering will be allocated to finance ongoing preclinical and clinical degrader programs, as well as for working capital and general corporate purposes [4]. Underwriter Option - In conjunction with the share offering, Kymera granted underwriters the option to purchase an additional $75 million at the public offer price [5].

Core Insights - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing degrader medicines for immunological diseases [1][4] - Barclays has set a price target of $119 for Kymera, indicating a potential price increase of 26.19% from its current price of $94.30 [1][5] Financial Developments - Kymera announced a public offering of $500 million in common stock, with an option for underwriters to purchase an additional $75 million to fund its pipeline [2][5] - The completion of the offering depends on market conditions, which could significantly impact the company's financial position and stock performance [2] Stock Performance - The stock has increased by 41.55%, or $27.68, reflecting investor confidence in Kymera's growth potential [3][5] - On the day of the announcement, KYMR's stock fluctuated between $86.84 and $103, indicating market volatility [3] - Over the past year, the stock reached a high of $103 and a low of $19.45, showcasing its dynamic nature [3] Market Position - Kymera's market capitalization is approximately $6.78 billion, highlighting its substantial presence in the biopharmaceutical sector [4] - The company's focus on innovative treatments for immunological diseases positions it as a key player in the industry [4]

Core Viewpoint - Kymera Therapeutics has received a "Buy" rating upgrade from Citigroup, reflecting strong confidence in its future prospects driven by successful clinical trials for its drug KT-621 [1][5] Company Developments - Kymera's KT-621 has shown substantial STAT6 degradation and strong clinical efficacy in Phase 1b trials for atopic dermatitis, leading to its advancement to Phase 2b trials for both atopic dermatitis and asthma [2][5] - The company's market capitalization is approximately $6.78 billion, indicating significant growth potential in the Type-2 inflammatory disease markets [4] Stock Performance - Following the positive trial outcomes, KYMR's stock price surged by $27.68, representing a 41.55% increase, reaching a high of $103, the peak in the past year [3][5] - The increase in stock price reflects investor optimism regarding the commercial potential of KT-621 and Kymera's validated protein-degradation platform [3][5] Analyst Insights - Citigroup has raised its price target for KYMR from $80 to $110, indicating strong confidence in the company's future performance [1][5]

Core Insights - Kymera Therapeutics (KYMR) shares surged 41.6% following positive results from the phase Ib BroADen study for its lead candidate KT-621, aimed at treating atopic dermatitis (AD) [1][4] - Year-to-date, Kymera's shares have increased by 134.4%, significantly outperforming the industry average rise of 19.3% [2] Study Results - The phase Ib BroADen study was an open-label, single-arm trial assessing KT-621 at doses of 100 mg and 200 mg in patients with moderate-to-severe AD [4] - KT-621 demonstrated deep STAT6 degradation, with median reductions of 94% in skin and 98% in blood, indicating effective translation of results from healthy volunteers to AD patients [4] - Significant reductions in type 2 biomarkers were observed, including a median 74% reduction in TARC levels, comparable to results from Sanofi's Dupixent studies [5] - The study reported a mean 63% reduction in the Eczema Area and Severity Index (EASI) and a mean 40% reduction in pruritus Numerical Rating Scale (NRS) [6] Clinical Activity and Safety - KT-621 showed strong clinical activity across all endpoints, with notable improvements in EASI and pruritus, as well as benefits for asthma and allergic rhinitis patients [6][7] - The treatment was well-tolerated, with no serious adverse side effects reported [7] Future Development - Kymera has advanced KT-621 into a phase IIb study, BROADEN2, with data expected by mid-2027 [9] - The company plans to initiate another phase IIb study, BREADTH, for moderate-to-severe asthma patients in Q1 2026 [9] - Conducting parallel phase IIb studies in AD and asthma is anticipated to expedite KT-621's development and inform dosing strategies for future phase III trials [10]